These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 36283893)
1. Risk of malignant hyperthermia in patients carrying a variant in the skeletal muscle ryanodine receptor 1 gene. Janssens L; De Puydt J; Milazzo M; Symoens S; De Bleecker JL; Herdewyn S Neuromuscul Disord; 2022 Dec; 32(11-12):864-869. PubMed ID: 36283893 [TBL] [Abstract][Full Text] [Related]
2. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met. Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814 [TBL] [Abstract][Full Text] [Related]
3. Functional characterisation of the R2452W ryanodine receptor variant associated with malignant hyperthermia susceptibility. Roesl C; Sato K; Schiemann A; Pollock N; Stowell KM Cell Calcium; 2014 Sep; 56(3):195-201. PubMed ID: 25086907 [TBL] [Abstract][Full Text] [Related]
4. Muscle biopsy and in vitro contracture test in subjects with idiopathic HyperCKemia. Malandrini A; Orrico A; Gaudiano C; Gambelli S; Galli L; Berti G; Tegazzin V; Dotti MT; Federico A; Sorrentino V Anesthesiology; 2008 Oct; 109(4):625-8. PubMed ID: 18813041 [TBL] [Abstract][Full Text] [Related]
5. Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia. Parker R; Schiemann AH; Langton E; Bulger T; Pollock N; Bjorksten A; Gillies R; Hutchinson D; Roxburgh R; Stowell KM J Neuromuscul Dis; 2017; 4(2):147-158. PubMed ID: 28527222 [TBL] [Abstract][Full Text] [Related]
6. Similar susceptibility to halothane, caffeine and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia. Ginz HF; Girard T; Censier K; Urwyler A Eur J Anaesthesiol; 2004 Feb; 21(2):151-7. PubMed ID: 14977348 [TBL] [Abstract][Full Text] [Related]
8. Malignant hyperthermia: a pharmacogenetic disease of Ca++ regulating proteins. Nelson TE Curr Mol Med; 2002 Jun; 2(4):347-69. PubMed ID: 12108947 [TBL] [Abstract][Full Text] [Related]
9. Identification of genetic mutations in Australian malignant hyperthermia families using sequencing of RYR1 hotspots. Gillies RL; Bjorksten AR; Davis M; Du Sart D Anaesth Intensive Care; 2008 May; 36(3):391-403. PubMed ID: 18564801 [TBL] [Abstract][Full Text] [Related]
10. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations. Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923 [TBL] [Abstract][Full Text] [Related]
11. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response. Steinfath M; Singh S; Scholz J; Becker K; Lenzen C; Wappler F; Köchling A; Roewer N; Schulte am Esch J J Mol Med (Berl); 1995 Jan; 73(1):35-40. PubMed ID: 7633940 [TBL] [Abstract][Full Text] [Related]
12. Effects of ryanodine on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis. Bina S; Muldoon S; Bünger R Eur J Anaesthesiol; 2008 Jan; 25(1):48-57. PubMed ID: 17686208 [TBL] [Abstract][Full Text] [Related]
13. RYR1 variant c.38T>G, p.Leu13Arg causes hypersensitivity of the ryanodine receptor-1 and is pathogenic for malignant hyperthermia. van den Bersselaar LR; Greven T; Bulger T; Voermans NC; van Petegem F; Schiemann AH; Parker R; Burling SM; Jungbluth H; Stowell KM; Kamsteeg EJ; Snoeck MMJ Br J Anaesth; 2021 Aug; 127(2):e63-e65. PubMed ID: 34127251 [No Abstract] [Full Text] [Related]
14. Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA. Sato K; Pollock N; Stowell KM Anesthesiology; 2010 Jun; 112(6):1350-4. PubMed ID: 20461000 [TBL] [Abstract][Full Text] [Related]